Bill Tella Joins DW Healthcare Partners

Bill Tella, former president of Curative Specialty Pharma, has joined DW Healthcare Partners as an executive-in-residence.


DW Healthcare Partners (DWHP), a healthcare focused private equity firm with over $250 million in committed capital under management, today announced that Mr. William Tella, former President of Curative Specialty Pharmacy, will join DWHP’s Executive in Residence program.

DWHP’s Executive in Residence program engages veteran corporate-level executives with exceptional track records to run and consult with their portfolio companies. We are thrilled to have Bill join our EIR program. His breadth of knowledge will enable us to identify and operate a world-class specialty pharmacy business within our portfolio,” said Andrew Carragher, Founder and Managing Director DWHP. Bill Tella brings over 20 years of experience in the healthcare service industry to DW Healthcare. Bill has led three healthcare companies, taking one from start-up to over $225 million in revenue.

As President of Curative Specialty Pharmacy, Bill was responsible for the identification and integration of over 11 acquisitions resulting in one of the largest national specialty pharmacy distributors. Curative was subsequently sold to Medco. “I am excited to join the Executive in Residence program and to work with the DW Healthcare Team as we actively look to enter the expanding Specialty Pharmacy sector. They have an exceptional team of healthcare executives with in-depth strategic knowledge to support our expansion efforts,” said Bill Tella.

About DW Healthcare Partners
DW Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. The firm manages over $250 million in committed capital and invests in profitable healthcare companies with proven management teams. DW Healthcare Partners is led by seasoned healthcare executives with more than 100 years of combined industry experience. The firm provides the capital, strategic guidance, and acquisition expertise to help mid- to late-stage companies realize their potential for growth.